Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Muscular dystrophy].

Eri Kondo1, Kayoko Saito, Makiko Osawa

  • 1Department of Pediatrics, Tokyo Women' s Medical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.

Annals of clinical and translational neurology·2026
Same author

Kangaroo mother care and maternal bonding 1 year after childbirth: a nationwide birth cohort-the Japan environment and children's cohort study.

BMC pregnancy and childbirth·2026
Same author

Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report.

Brain & development·2026
Same author

Reply to "Comment on 'Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment'".

Brain & development·2025
Same author

Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations.

Journal of neuromuscular diseases·2025
Same author

Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment.

Brain & development·2025

Muscular dystrophies are genetic disorders affecting skeletal muscle. Advances in molecular genetics and diagnostic tools like muscle biopsy and genetic testing aid in understanding and managing these progressive conditions.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Context:

  • Muscular dystrophies represent a diverse group of progressive genetic disorders impacting skeletal muscle integrity.
  • Recent molecular genetics research has significantly advanced the understanding of this complex family of diseases.

Purpose:

  • To explore the diagnostic utility of muscle biopsy and genetic testing in various muscular dystrophies.
  • To highlight the role of molecular genetics in classifying and understanding muscular dystrophy subtypes.
  • To consider the ethical implications associated with genetic testing for muscular dystrophies.

Summary:

  • Muscle biopsy enables immunohistochemical analysis of muscle-specific proteins, crucial for definitive diagnosis.
  • Genetic testing offers a straightforward diagnostic approach for certain types, such as Duchenne and Fukuyama muscular dystrophies.

Related Experiment Videos

  • The integration of genetic diagnostic data is paving the way for novel therapeutic strategies and clinical applications.

    • Impact:

    • Improved diagnostic accuracy and classification of muscular dystrophy subtypes.
    • Facilitation of personalized treatment approaches based on genetic profiles.
    • Advancement of research towards effective therapeutic interventions for muscular dystrophies.